Autologous Tregs for Aplastic Anaemia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This Phase I study will determine the safety and optimal dose of expanded autologous Tregs to treat patients with Aplastic Anaemia (AA) (who have failed, or are considered ineligible for IST (immunosuppressive therapy) / other treatments) using expanded autologous T regulatory cells (Tregs) from AA patients at King\'s College Hospital, that have been prepared at the licensed Good Manufacturing Practices (GMP) production facility at Guy\'s Hospital, London
Epistemonikos ID: 0ee6cd6963d21cf91b9c9ba1c45eb4547bcbbb05
First added on: May 13, 2024